Roanna Ruiz
Stock Analyst at Leerink Partners
(0.90)
# 4,006
Out of 5,113 analysts
59
Total ratings
35.9%
Success rate
-12.72%
Average return
Main Sectors:
Stocks Rated by Roanna Ruiz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IBIO iBio, Inc. | Initiates: Outperform | $2 | $2.23 | -10.31% | 1 | Oct 17, 2025 | |
| XERS Xeris Biopharma Holdings | Maintains: Outperform | $7 → $9 | $7.16 | +25.70% | 7 | Aug 19, 2025 | |
| AKBA Akebia Therapeutics | Initiates: Outperform | $7 | $1.45 | +382.76% | 1 | Apr 28, 2025 | |
| CRMD CorMedix | Initiates: Outperform | $18 | $7.75 | +132.26% | 1 | Mar 7, 2025 | |
| LXRX Lexicon Pharmaceuticals | Downgrades: Market Perform | $1 | $1.50 | -33.33% | 1 | Mar 4, 2025 | |
| VIR Vir Biotechnology | Maintains: Outperform | $18 → $20 | $7.57 | +164.20% | 4 | Jan 13, 2025 | |
| SPRY ARS Pharmaceuticals | Maintains: Outperform | $26 → $27 | $10.06 | +168.39% | 4 | Jan 13, 2025 | |
| AQST Aquestive Therapeutics | Maintains: Outperform | $12 → $13 | $3.24 | +301.23% | 3 | Oct 25, 2024 | |
| ARDX Ardelyx | Initiates: Outperform | $14 | $7.86 | +78.12% | 1 | Apr 5, 2024 | |
| UTHR United Therapeutics | Initiates: Outperform | $330 | $467.30 | -29.38% | 1 | Feb 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $58 | $65.14 | -10.96% | 1 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $25 | $45.85 | -45.47% | 1 | Apr 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | $49 | $12.65 | +287.35% | 10 | Feb 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $8 → $6 | $3.87 | +55.04% | 6 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $31.88 | -40.40% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $110 → $120 | $66.31 | +80.97% | 3 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $75 → $50 | $8.06 | +520.35% | 7 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $60 → $40 | $15.07 | +165.43% | 6 | Oct 19, 2022 |
iBio, Inc.
Oct 17, 2025
Initiates: Outperform
Price Target: $2
Current: $2.23
Upside: -10.31%
Xeris Biopharma Holdings
Aug 19, 2025
Maintains: Outperform
Price Target: $7 → $9
Current: $7.16
Upside: +25.70%
Akebia Therapeutics
Apr 28, 2025
Initiates: Outperform
Price Target: $7
Current: $1.45
Upside: +382.76%
CorMedix
Mar 7, 2025
Initiates: Outperform
Price Target: $18
Current: $7.75
Upside: +132.26%
Lexicon Pharmaceuticals
Mar 4, 2025
Downgrades: Market Perform
Price Target: $1
Current: $1.50
Upside: -33.33%
Vir Biotechnology
Jan 13, 2025
Maintains: Outperform
Price Target: $18 → $20
Current: $7.57
Upside: +164.20%
ARS Pharmaceuticals
Jan 13, 2025
Maintains: Outperform
Price Target: $26 → $27
Current: $10.06
Upside: +168.39%
Aquestive Therapeutics
Oct 25, 2024
Maintains: Outperform
Price Target: $12 → $13
Current: $3.24
Upside: +301.23%
Ardelyx
Apr 5, 2024
Initiates: Outperform
Price Target: $14
Current: $7.86
Upside: +78.12%
United Therapeutics
Feb 5, 2024
Initiates: Outperform
Price Target: $330
Current: $467.30
Upside: -29.38%
Aug 15, 2023
Initiates: Outperform
Price Target: $58
Current: $65.14
Upside: -10.96%
Apr 11, 2023
Initiates: Market Perform
Price Target: $25
Current: $45.85
Upside: -45.47%
Feb 9, 2023
Reiterates: Market Perform
Price Target: $49
Current: $12.65
Upside: +287.35%
Jan 27, 2023
Maintains: Market Perform
Price Target: $8 → $6
Current: $3.87
Upside: +55.04%
Dec 20, 2022
Initiates: Outperform
Price Target: $19
Current: $31.88
Upside: -40.40%
Nov 15, 2022
Maintains: Outperform
Price Target: $110 → $120
Current: $66.31
Upside: +80.97%
Nov 3, 2022
Maintains: Market Perform
Price Target: $75 → $50
Current: $8.06
Upside: +520.35%
Oct 19, 2022
Maintains: Market Perform
Price Target: $60 → $40
Current: $15.07
Upside: +165.43%